checkAd
    Startseite > Aktien > VBI Vaccines > Nachrichten
    VBI Vaccines Aktie
    0,5740
     
    USD
    -4,24 %
    -0,0254 USD
    Letzter Kurs 27.04.24 Nasdaq
    0,5615
     
    USD
    600 STK
    Geldkurs 26.04.24
    0,5824
     
    USD
    200 STK
    Briefkurs 26.04.24
    ISIN: CA91822J2020 · WKN: A3D9SJ · SYM: VBIV · Kanada

    Neueste Nachrichten

    VBI Vaccines Reports Full Year 2023 Financial Results
    16.04.24 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    11.04.24 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
    09.04.24 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
    03.04.24 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
    02.04.24 · Business Wire (engl.) · VBI Vaccines
    VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
    14.02.24 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
    20.11.23 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Reports Third Quarter 2023 Financial Results
    14.11.23 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
    26.10.23 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
    27.09.23 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
    07.09.23 · Business Wire (engl.) · VBI Vaccines
    VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
    06.09.23 · Business Wire (engl.) · VBI Vaccines